دسترسی نامحدود
برای کاربرانی که ثبت نام کرده اند
برای ارتباط با ما می توانید از طریق شماره موبایل زیر از طریق تماس و پیامک با ما در ارتباط باشید
در صورت عدم پاسخ گویی از طریق پیامک با پشتیبان در ارتباط باشید
برای کاربرانی که ثبت نام کرده اند
درصورت عدم همخوانی توضیحات با کتاب
از ساعت 7 صبح تا 10 شب
ویرایش: 1
نویسندگان: Mark Horowitz. David Taylor.
سری:
ISBN (شابک) : 9781119823025, 9781119822981
ناشر: Wiley
سال نشر: 2024
تعداد صفحات: 591
زبان: English
فرمت فایل : PDF (درصورت درخواست کاربر به PDF، EPUB یا AZW3 تبدیل می شود)
حجم فایل: 426 مگابایت
در صورت تبدیل فایل کتاب The Maudsley Deprescribing Guidelines in Psychiatry: Antidepressants, Benzodiazepines, Gabapentinoids and Z-drugs / به فرمت های PDF، EPUB، AZW3، MOBI و یا DJVU می توانید به پشتیبان اطلاع دهید تا فایل مورد نظر را تبدیل نمایند.
توجه داشته باشید کتاب دستورالعملهای توصیفی مادزلی در روانپزشکی: داروهای ضد افسردگی، بنزودیازپینها، گاباپنتینوئیدها و داروهای Z. نسخه زبان اصلی می باشد و کتاب ترجمه شده به فارسی نمی باشد. وبسایت اینترنشنال لایبرری ارائه دهنده کتاب های زبان اصلی می باشد و هیچ گونه کتاب ترجمه شده یا نوشته شده به فارسی را ارائه نمی دهد.
TABLE OF CONTENTS Preface ix Acknowledgements xii Notes on Using the Maudsley® Deprescribing Guidelines xiii Abbreviations List xv Chapter 1 Introduction to Deprescribing Psychiatric Medications 1 Deprescribing as an Intervention 1 The context for deprescribing 2 Why deprescribe? 7 Barriers and facilitators to deprescribing 11 Withdrawal Effects from Psychiatric Medications 13 Mis-diagnosis of withdrawal effects as relapse 13 Pathophysiology of psychiatric drug withdrawal symptoms 16 Clinical aspects of psychiatric drug withdrawal 19 Specific issues in psychiatric drug withdrawal 23 How to Deprescribe Psychiatric Medications Safely 27 The neurobiology of tapering 28 Practical options for prescribing gradually tapering doses 36 Psychological aspects of tapering 43 Tapering psychiatric drugs in practice 45 Further topics 52 Chapter 2 Safe Deprescribing of Antidepressants 57 When and Why to Stop Antidepressants 57 Adverse effects of antidepressants 66 Discussing deprescribing antidepressants with patients 72 Withdrawal Effects from Antidepressants 76 Recent developments in the understanding of antidepressant withdrawal 76 Pathophysiology of antidepressant withdrawal symptoms 80 Clinical aspects of antidepressant withdrawal 87 How common, severe and long‐ lasting are withdrawal symptoms from antidepressants? 92 Protracted antidepressant withdrawal syndrome 96 Post‐ SSRI sexual dysfunction 98 Factors influencing development of withdrawal effects 99 Stratfiying risk of antidepressant withdrawal 105 Distinguishing antidepressant withdrawal symptoms from relapse 107 Distinguishing antidepressant withdrawal symptoms from new onset of a physical or mental health condition 111 Withdrawal symptoms during antidepressant maintenance treatment or switching medication 113 How to Deprescribe Antidepressants Safely 115 Tapering antidepressants gradually 119 Hyperbolic tapering of antidepressants 125 Practical options in prescribing gradually tapering doses of antidepressants 131 Psychological aspects of antidepressant tapering 140 Tapering antidepressants in practice 143 Managing complications of antidepressant discontinuation 153 Tapering Guidance for Specific Antidepressants 158 Agomelatine 159 Amitriptyline 163 Bupropion 168 Citalopram 174 Clomipramine 183 Desvenlafaxine 188 Dosulepin 193 Doxepin 198 Duloxetine 203 Escitalopram 209 Fluoxetine 216 Fluvoxamine 223 Imipramine 228 Lofepramine 233 Mirtazapine 238 Moclobemide 243 Nortriptyline 248 Paroxetine 253 Phenelzine 259 Sertraline 264 Tranylcypromine 270 Trazodone 275 Venlafaxine 280 Vilazodone 288 Vortioxetine 292 Chapter 3 Safe Deprescribing of Benzodiazepines and Z-drugs 297 When and Why to Stop Benzodiazepines and Z-drugs 297 Discussing deprescribing benzodiazepines and z-drugs 304 Withdrawal Symptoms from Benzodiazepines and Z-drugs 309 Physical dependence vs addiction in use of benzodiazepines and z-drugs 311 Pathophysiology of benzodiazepine withdrawal syndrome 313 Variety of withdrawal symptoms from benzodiazepines and z-drugs 316 Protracted benzodiazepine withdrawal syndrome 320 Distinguishing benzodiazepine withdrawal symptoms from return of an underlying condition 323 Withdrawal symptoms during benzodiazepine maintenance treatment 326 How to Deprescribe Benzodiazepines and Z-drugs Safely 327 Tapering benzodiazepines and z-drugs gradually 330 Hyperbolic tapering of benzodiazepines and z-drugs 332 Switching to longer-acting benzodiazepines to taper 335 Making up smaller doses of benzodiazepines and z-drugs practically 338 Other considerations in tapering benzodiazepines and z-drugs 342 Psychological aspects of tapering benzodiazepines and z-drugs 345 Tapering benzodiazepines and z-drugs in practice 348 Management of complications of benzodiazepine and z-drug discontinuation 358 Tapering Guidance for Specific Benzodiazepines and Z-drugs 362 Alprazolam 364 Buspirone 375 Chlordiazepoxide 380 Clonazepam 388 Clorazepate 396 Diazepam 404 Estazolam 412 Eszopiclone 418 Flurazepam 423 Lorazepam 429 Lormetazepam 440 Nitrazepam 446 Oxazepam 452 Quazepam 461 Temazepam 467 Triazolam 474 Zaleplon 480 Zolpidem 485 Zopiclone 490 Chapter 4 Safe Deprescribing of Gabapentinoids 495 When and Why to Stop Gabapentinoids 495 Discussing deprescribing gabapentinoids 504 Overview of Gabapentinoid Withdrawal Effects 507 Physical dependence vs addiction in use of gabapentinoids 510 How to Deprescribe Gabapentinoids Safely 512 Principles for tapering gabapentinoids 512 Making up smaller doses of gabapentinoids practically 516 Other considerations in tapering gabapentinoids 520 Psychological aspects of tapering gabapentinoids 523 Tapering gabapentinoids in practice 525 Management of complications of gabapentinoid discontinuation 532 Tapering Guidance for Specific Gabapentinoids 537 Gabapentin 538 Pregabalin 546 Index 553